- By insider

President and CEO of Denali Therapeutics Inc (30-Year Financial, Insider Trades) Ryan J. Watts (insider trades) sold 88,334 shares of DNLI on 01/04/2021 at an average price of $74.96 a share. The total sale was $6.6 million.

• Warning! GuruFocus has detected 3 Warning Signs with DNLI. Click here to check it out.

• DNLI 15-Year Financial Data

• The intrinsic value of DNLI

• Peter Lynch Chart of DNLI

Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Denali Therapeutics Inc has a market cap of $8.16 billion; its shares were traded at around $68.040000 with and P/S ratio of 301.07. GuruFocus has detected 2 severe warning signs with Denali Therapeutics Inc. .

CEO Recent Trades:

• President and CEO Ryan J. Watts sold 88,334 shares of DNLI stock on 01/04/2021 at the average price of $74.96. The price of the stock has decreased by 9.23% since.

Directors and Officers Recent Trades:

• COO and Secretary Alexander O. Schuth sold 70,000 shares of DNLI stock on 01/04/2021 at the average price of $74.95. The price of the stock has decreased by 9.22% since.

• Director David P Schenkein sold 30,000 shares of DNLI stock on 12/21/2020 at the average price of $90.05. The price of the stock has decreased by 24.44% since.

• 10% Owner Douglas K Bratton sold 64,624 shares of DNLI stock on 12/14/2020 at the average price of $80.14. The price of the stock has decreased by 15.1% since.

For the complete insider trading history of DNLI, click here

.This article first appeared on GuruFocus.